DOCS Stock Price Today (October 2026) — Doximity, Inc. Analysis & Key Metrics 2026-10-21
Doximity, Inc. (DOCS) is trading at $33.35, up 6.04% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $30.44 (8.7% downside).
- Volatility is high (40.56% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.30% YoY) alongside competitive pressures in the Health Information Services space.
DOCS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Doximity, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $5.27B
P/E Ratio
Forward P/E: 17.24
Revenue Growth
Year over Year
Analyst Target
-8.7% downside from target
Key Investor Questions About DOCS
What investors need to know before buying
Based on current market data, DOCS presents a overbought technical setup with looking solid fundamentals.
- Technicals say: Overbought (RSI 78.17)
- Fundamentals say: Looking solid (debt and growth supportive)
DOCS's growth trajectory depends on its ability to expand within the Health Information Services sector while managing margin pressures.
- Future growth will depend on performance in core Health Information Services operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DOCS investors include debt exposure and competitive dynamics in the Health Information Services industry.
- $9.67M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Health Information Services.
52-Week Trading Range
Over the past year, DOCS stock traded between $17.15 and $71.37 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 40.56% annualized volatility and β=0.82, the stock exhibits low sensitivity to market moves—making DOCS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Why Is Doximity (DOCS) Stock Rocketing Higher Today
OpenEvidence, Doximity settle thorny AI legal battle
Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask
BofA Securities Adjusts Price Target on Doximity to $23 From $20, Maintains Underperform Rating
Why Doximity (DOCS) Dipped More Than Broader Market Today
Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
Latest TickZen Insights
All insights →No TickZen article on DOCS yet. Our newest analysis:
Explore More Analysis for DOCS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Doximity, Inc.
Doximity, Inc. (DOCS) is currently trading at $33.35. The RSI (14-day) is at 78.2, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $30.44 implies 8.7% downside from current levels. Volatility is high at 40.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Doximity, Inc. (DOCS): The trailing P/E ratio is 31.42, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 17.24, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.59, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 5.18. Price-to-Sales is 5.13. Valuation should be compared to Health Information Services industry peers for context, as different sectors trade at different multiples.
Based on 18 analysts covering DOCS, the consensus price target is $30.44. This represents a 8.7% downside from the current price of $33.35. The range spans from a low target of $18.00 to a high target of $47.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Doximity, Inc. (DOCS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Doximity, Inc. (DOCS) investors include: 1. High volatility (40.6% annualized)—the stock can experience significant daily price swings. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Health Information Services sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Doximity, Inc.'s (DOCS) current debt and financial health profile: Total debt stands at $9.67M. The debt-to-equity ratio is 0.01x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.08, indicating strong short-term liquidity. The quick ratio is 5.80. The company holds $687.79M in cash and equivalents. Free cash flow is positive at $239.70M, providing a cushion for debt servicing and shareholder returns.